Exosome Diagnostics, Inc.
10
0
1
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
10.0%
1 terminated/withdrawn out of 10 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Molecular Studies and Clinical Correlations in Human Prostatic Disease
Role: collaborator
ExoDx Prostate Evaluation in Active Surveillance Patient Population
Role: lead
Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)
Role: lead
Decision Impact Trial of the ExoDx Prostate (IntelliScore)
Role: lead
ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting
Role: lead
Urine Biomarker for Kidney Transplant Rejection
Role: lead
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
Role: lead
Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy
Role: lead
Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI)
Role: lead
Clinical Validation of a Urinary Exosome Gene Signature in Men Presenting for Suspicion of Prostate Cancer
Role: lead
All 10 trials loaded